View Older Stories View More Recent Stories

Apr 23, 2026 08:01AM Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
Apr 20, 2026 08:00AM Ardelyx names Felecia Ettenberg as chief legal officer
Apr 20, 2026 08:00AM Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
Apr 16, 2026 08:01AM Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Apr 16, 2026 08:01AM Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Apr 1, 2026 08:01AM Ardelyx names Rajani Dinavahi as chief medical officer
Apr 1, 2026 08:01AM Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
Mar 12, 2026 08:00AM Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Mar 9, 2026 04:05PM Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Mar 4, 2026 08:00AM Ardelyx to Participate in Upcoming Investor Conferences
Feb 24, 2026 08:00AM Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
Feb 19, 2026 04:01PM Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 5, 2026 08:00AM Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Feb 3, 2026 08:29AM Ardelyx receives patent for tenapanor formulations expiring in 2042
Feb 3, 2026 08:29AM Ardelyx Receives New Patent for Tenapanor
Jan 28, 2026 08:29AM Ardelyx begins Phase 3 trial of IBSRELA for chronic constipation
Jan 28, 2026 08:29AM First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
Jan 8, 2026 09:49AM Ardelyx reports $378 million in 2025 revenue, projects growth
Jan 8, 2026 08:30AM Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Nov 7, 2025 04:05PM Ardelyx presents real-world data on XPHOZAH at kidney conference
Nov 7, 2025 04:05PM Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
Nov 5, 2025 08:00AM Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Nov 4, 2025 08:00AM Ardelyx CEO to speak at Wedbush nephrology conference
Nov 4, 2025 08:00AM Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
Oct 30, 2025 04:01PM Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 28, 2025 08:02AM Ardelyx presents IBSRELA data at gastroenterology meeting
Oct 28, 2025 08:01AM Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
Oct 21, 2025 08:00AM Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
Oct 13, 2025 08:35AM Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Oct 13, 2025 08:30AM Ardelyx names Sue Hohenleitner as chief financial officer
Oct 13, 2025 08:30AM Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
Aug 25, 2025 08:00AM Ardelyx to Participate in Upcoming Investor Conferences
Aug 4, 2025 04:09PM Ardelyx names new medical officer, technical operations chief
Aug 4, 2025 04:08PM Ardelyx Announces Changes to the Executive Leadership Team
Aug 4, 2025 04:01PM Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 21, 2025 08:00AM Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Jun 2, 2025 04:05PM Ardelyx (ARDX) appoints new CBO and CHRO
Jun 2, 2025 04:05PM Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
May 21, 2025 08:00AM Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
May 6, 2025 08:02AM Ardelyx (ARDX) Presents Data Supporting IBSRELA
May 6, 2025 08:01AM Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
May 1, 2025 04:01PM Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 29, 2025 08:00AM Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
Apr 24, 2025 08:01AM Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
Apr 17, 2025 08:00AM Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Apr 10, 2025 04:03PM Ardelyx (ARDX): Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH to be Presented
Apr 10, 2025 04:02PM Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
Mar 31, 2025 04:04PM Ardelyx (ARDX) to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
Mar 31, 2025 04:03PM Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
Mar 13, 2025 08:03AM Ardelyx (ARDX) Announces the First Recipients of Derek Forfang Patient Advocate Award
View More Recent Stories View Older Stories